Inhibition of Daptomycin by Pulmonary Surfactant: In Vitro Modeling and Clinical Impact

Jared Silverman, Lawrence I. Mortin, Andrew D. G. VanPraagh, +2

The Journal of Infectious Diseases

Pharmaceutical SciencePulmonary SurfactantAntimicrobial ChemotherapyClinical ImpactDrug Resistance +14

Genetic Changes That Correlate with Reduced Susceptibility to Daptomycin in <i>Staphylococcus aureus</i>

Lisa Friedman, Jeff Alder, Jared Silverman

Antimicrobial Agents and Chemotherapy

GeneticsMolecular BiologyAntibiotic ResistanceBacterial PathogensDrug Resistance +18

Bactericidal Action of Daptomycin against Stationary-Phase and Nondividing <i>Staphylococcus aureus</i> Cells

Carmela Mascio, Jeff Alder, Jared Silverman

Antimicrobial Agents and Chemotherapy

Antimicrobial ChemotherapyDrug ResistanceInfection ControlAntibacterial MechanismsAntimicrobial Resistance +15

Induction of Daptomycin Heterogeneous Susceptibility in <i>Staphylococcus aureus</i> by Exposure to Vancomycin

George Sakoulas, Jeff Alder, C Thauvin-Eliopoulos, +2

Antimicrobial Agents and Chemotherapy

Antimicrobial ChemotherapyAntibiotic ResistanceBacterial PathogensDrug ResistanceInfection Control +15

Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis: a phase II randomised study

Robert Wilson, Tobias Welte, Eva Polverino, +6

European Respiratory Journal

Pulmonary CareInflammatory Lung DiseaseAdvanced Lung DiseaseLung InflammationRespiratory Infection +15

Effects of Prior Effective Therapy on the Efficacy of Daptomycin and Ceftriaxone for the Treatment of Community‐Acquired Pneumonia

Peter Pertel, Patricia Bernardo, Charles Fogarty, +7

Clinical Infectious Diseases

Efficacy of Daptomycin in Experimental Endocarditis Due to Methicillin-Resistant <i>Staphylococcus</i> <i>aureus</i>

George Sakoulas, George M. Eliopoulos, Jeff Alder, +1

Antimicrobial Agents and Chemotherapy

Inhaled amikacin adjunctive to intravenous standard-of-care antibiotics in mechanically ventilated patients with Gram-negative pneumonia (INHALE): a double-blind, randomised, placebo-controlled, phase 3, superiority trial

Michael S. Niederman, Jeff Alder, Matteo Bassetti, +12

The Lancet Infectious Diseases

Superiority TrialPulmonary CareAntibioticsRespiratory InfectionInfectious Respiratory Disease +5

A comprehensive regulatory framework to address the unmet need for new antibacterial treatments

John Rex, Barry I. Eisenstein, Jeff Alder, +9

The Lancet Infectious Diseases

Antimicrobial SusceptibilityNew Antibacterial TreatmentsAntibioticsUnmet NeedComprehensive Regulatory Framework +8

Novel Erythromycin Derivatives with Aryl Groups Tethered to the C-6 Position Are Potent Protein Synthesis Inhibitors and Active against Multidrug-Resistant Respiratory Pathogens

Zhenkun Ma, Richard F. Clark, Antony Brazzale, +21

Journal of Medicinal Chemistry

Bioorganic ChemistryAntibiotic AdjuvantAntimicrobial ChemotherapyAryl Groups TetheredDrug Resistance +17